CD34+ CD38−LSCs frequency is associated with worse outcomes namely remission and survival [5]; AML patients with greater than 3.5% of CD34+CD38- LSCs show a median relapse free survival of 5.6 mo vs. 16 mo in those with a lower percentage of CD34+CD38- cells [5]. This evidence concerns the gene CD38 and acute myeloid leukemia.